Key result
Semaglutide cuts major adverse cardiovascular events ~20% in patients with CVD and overweight or obesity.
Why the study?
Obesity is a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. This review synthesizes mechanistic and clinical evidence on semaglutide and other novel anti-obesity pharmacotherapies for cardiovascular risk reduction in resource-constrained healthcare systems.
Does semaglutide reduce cardiovascular events and improve cardiometabolic risk markers in individuals with obesity in resource-limited settings?
Does semaglutide reduce cardiovascular events and improve cardiometabolic risk markers in individuals with obesity in resource-limited settings?
This review synthesizes the mechanistic and clinical evidence supporting semaglutide for obesity management and cardiovascular risk reduction, emphasizing tailored implementation strategies for resource-limited healthcare systems like Indonesia.
Answers are grounded in this paper and cite their sources.
Supports semaglutide for weight loss and MACE reduction in obesity with CVD; confirms trial benefits while leaving scalable implementation open in resource-limited settings.
Obesity represents a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. Excess adiposity promotes cardiometabolic dysfunction through interconnected pathways involving insulin resistance, chronic low-grade inflammation, dyslipidemia, neurohormonal activation, and adverse cardiac remodeling, ultimately increasing the risk of heart failure, ischemic heart disease, stroke, and major adverse cardiovascular events. Among emerging therapeutic targets, incretin-based pathways have gained particular attention because they address both weight reduction and cardiovascular risk modification. Semaglutide, a glucagon-like peptide-1 receptor agonist, has become one of the most clinically relevant agents in this field, with evidence showing substantial reductions in body weight and improvements in glycemic control, visceral adiposity, systemic inflammation, blood pressure, and cardiometabolic risk markers. Data further support the potential role of semaglutide in reducing cardiovascular events, including among individuals with obesity and established cardiovascular disease without type 2 diabetes. The aim of the review is to synthesize current mechanistic and clinical evidence on semaglutide as an emerging therapeutic strategy in obesity management for cardiovascular risk reduction, while briefly contextualizing its role among other novel anti-obesity pharmacotherapies. Particular attention is also given to the relevance of semaglutide in resource-limited settings. Understanding organ-specific mechanisms and prioritizing scalable interventions may support more effective cardiovascular disease risk reduction strategies in obesity within resource-constrained healthcare systems.
No takes yet. Share an insight, caveat, or question.
Arifianto et al. (2026) conducted a review in Obesity and cardiovascular disease. Semaglutide vs. Placebo or alternative anti-obesity strategies (lifestyle modification, tirzepatide) was evaluated. Semaglutide achieves 15–18.7% weight loss and reduces major adverse cardiovascular events by 20% in patients with overweight or obesity and cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: